Legend Biotech Plans 20,000-Dose Carviti Capacity Boost, Seeks 50% Growth
Legend Biotech expanded Carviti manufacturing capacity to 10,000 doses with plans to double to 20,000, aiming to support 50% top-line growth in 2026 across U.S. and international markets. Clinical data showed median progression-free survival of 50.4 months, while CAR T penetration remains below 5% in later-line multiple myeloma.
1. Manufacturing Expansion
Legend Biotech has expanded Carviti manufacturing capacity to 10,000 doses annually and is investing in infrastructure to reach 20,000 doses, aiming to meet rising patient demand and support broader treatment adoption.
2. Clinical Efficacy Data
Clinical analyses show patients treated early with Carviti achieved a median progression-free survival of 50.4 months, highlighting the therapy’s durable efficacy in second to fourth-line multiple myeloma.
3. Market Dynamics
Competitive activity is rising after Gilead’s recent acquisition of a CAR T rival, validating BCMA-targeted therapy value; yet under 5% of eligible multiple myeloma patients received BCMA agents in 2025, underscoring significant growth potential.
4. 2026 Growth Outlook
Management forecasts approximately 50% top-line growth in 2026, with a balanced rollout between U.S. and international markets and initiatives to drive adoption through community hospitals and updated treatment guidelines.